{
    "nctId": "NCT05327608",
    "briefTitle": "Intermittent Fasting for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery",
    "officialTitle": "Intermittent Fasting for Patients With HER2- Negative and ER/PR <10% Breast Cancer and Body Mass Index >= 25 Receiving Neoadjuvant Chemotherapy",
    "overallStatus": "SUSPENDED",
    "conditions": "Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma in Situ, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 55,
    "primaryOutcomeMeasure": "Proportion of patients who can adhere to to intermittent fasting",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient must be \\>= 18 years of age at time of consent and must be able to understand and provide informed consent\n* BMI \\>= 25 at time of enrollment\n* Patient must have a recent diagnosis of histologically confirmed primary invasive breast carcinoma\n\n  * Multifocal or contralateral ductal carcinoma in situ (DCIS) or invasive breast cancers are allowed if the breast cancers meet the same eligibility criteria for ER/PR and HER2\n  * Oligometastatic disease is allowed if treating physician recommends standard neoadjuvant chemotherapy\n* Tumor status must be HER2 negative per American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (determined by local testing)\n* ER and PR expression must be \\< 10% cells positive by immunohistochemestry (IHC) test\n* Patients must have clinical stage I-III (utilizing tumor, node, metastasis \\[TNM\\] criterion) at diagnosis\n* Clinical T size must be \\>= 1.5 cm if there is no radiographic or clinical evidence of axillary lymph node involvement. Any size tumor is allowed if axillary lymph nodes appear to be involved\n* Patient must be willing and able (have no contraindication) to receive recommended standard neoadjuvant therapy consisting of at least 16 weeks of planned neoadjuvant chemotherapy\n\n  \\* Acceptable regimen includes doxorubicin and cytoxan followed by paclitaxel (AC-T). The schedule will be determined by treating physician. Carboplatin and pembrolizumab can also be added to the neoadjuvant chemotherapy regimen if determined to be appropriate by treating physician\n* Patients must have organ and marrow function adequate for initiating neoadjuvant chemotherapy as determined by their treating physician\n* Women of childbearing potential and sexually active males must use accepted and effective method(s) of contraception or abstain from sexual intercourse for the duration of their participation in the study and for 6 months after the last study intervention\n\nExclusion Criteria:\n\n* Clinical T4 and/or N3 disease, including inflammatory breast cancer\n* Any prior treatment for the current breast cancer diagnosis, including surgery, chemotherapy, radiation, or experimental therapy\n* Women must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. Patients must also not expect to conceive from the time of registration, while on study treatment, and until at least 6 months after the last study intervention\n* Patients must not have impaired decision-making capacity\n* Patients who are not English speaking as study staff is only able to provide the study intervention measurement tool and behavioral lifestyle coaching in English\n* Patients that are \\> 2 weeks into starting neoadjuvant chemotherapy regimen",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}